Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751584 | 0.86 | APP (0.41) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL766601 | 0.83 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL766602 | 0.83 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14599499 | 0.79 | TP53 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL16445311 | 0.78 | PTGS1 (0.31) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL9488987 | 0.76 | TP53 (0.34) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL329794 | 0.76 | — | — | |
| SCHEMBL5026578 | 0.74 | — | — | |
| Ammonia Solution, Strong SCHEMBL18008481 | 0.74 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28099471 | 0.74 | PTGS1 (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| CN-104606681-B | Include the pharmaceutical composition and its preparation and application of prasugrel and cyclodextrine derivatives | 锡德克斯药物公司 | 2018-08-21 | — | — | CN | disclosed |
| US-9617289-B2 | RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-11 | — | — | US | disclosed |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-01-12 | — | — | US | disclosed |
| EP-3100728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9399067-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2429291-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9240614-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
| US-8835407-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2579377-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8236782-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2429291-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132711-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | PTGS1 217/4885PDE4A 47/4885LMNA 3458/4885 |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | PTGS1 217/4885PDE4A 47/4885LMNA 3458/4885 |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | PTGS1 217/4885PDE4A 47/4885LMNA 3458/4885 |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | P2RY6, GP6, PFKP | PTGS1 217/4885PDE4A 47/4885LMNA 3458/4885 |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | PTGS1 217/4885PDE4A 47/4885LMNA 3458/4885 |
| US-20150259367-A1 | RSV ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, RTF1 | PTGS1 1451/4885PDE4A 4053/4885LMNA 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.